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Abstract 
Anemia is common in cancer patients. Erythropoiesis-stimulating agents (ESAs) 
improve hemoglobin concentrations, decrease transfusion requirements and may improve 
quality of life. The American Society ofHematology (ASH) and the American Society 
of Clinical Oncology (ASCO) published guidelines for their use in 2002. The frrst 
objective was to estimate the number of patients with hematologic malignancies in 
Newfoundland and Labrador, who meet these criteria, that actually receive an ESA. The 
second objective was to determine whether there are demographic factors associated with 
receiving an ESA. The third objective was to review the literature around ESA use, 
tumor progression and survival. A review of the medical charts of 110 patients meeting 
the ASH/ ASCO guidelines was undertaken. Patients had an average hemoglobin of 89.1 
giL, spent 75% of the time with a hemoglobin under 100 giL and received an average of 
one transfusion every three weeks. More patients living in urban areas received an ESA 
than in rural areas. ESAs are important in supportive cancer care and measures should be 
taken to meet national standards. 
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Chapter 1: Introduction 
1.1. Background 
Anemia in patients with cancer has multiple etiologies, the most common of 
which are chemotherapy-related and cytokine-mediated anemia of chronic disease. 
Cancer-related anemia is very common in patients with hematologic malignancies and 
causes significant physical morbidity and impaired quality of life. 1 Cancer patients with 
anemia have significant fatigue, decreased physical and functional well-being and 
decreased ability to work. 2• 3 
While allogeneic red blood cell transfusions have traditionally been the mainstay 
of treatment for cancer-related anemia, they are associated with a variety of reactions, 
which range from mild allergic-type to severe reactions, like acute hemolytic transfusion 
reactions and transfusion-related acute lung injury (TRALI).4 Transfusions also have an 
associated risk of infectious disease transmission. While the risk of serious reactions and 
infectious disease transmission is low, when they occur they can be associated with 
significant morbidity and mortality. 
Erythropoiesis-stimulating agents (ESAs ), initially approved for the treatment of 
anemia associated with chronic kidney disease, have been demonstrated to improve 
hemoglobin concentrations or hematocrit levels5 and reduce transfusion requirements6 in 
patients with cancer-related anemia. There is some evidence that they improve quality of 
life in this population. 7 
Some safety concerns around the use of ESAs exist. They are known to increase 
the risk of thromboembolic disease8 and some recent data has suggested that they may 
adversely affect disease outcomes and mortality, particularly in patients not receiving 
chemotherapy.9 In many of these trials, however, the patients were not anemic 10and 
ESA doses were titrated to achieve hemoglobin concentrations higher than that 
recommended in published guidelines. 11 ' 12 As well, many of the studies of ESAs in 
cancer patients have not been powered to detect survival differences.8 More well-
powered, high-quality studies are needed to clarify this issue. 
1.2. Study Purpose 
Between 2001 and 2004, a variety of organizations11 ' 13' 14 developed evidenced-
based clinical practice guidelines for ESA use in patients with cancer-related anemia. It 
has been the experience of the hematologists and medical oncologists in the province of 
Newfoundland and Labrador that the majority of patients meeting these guideline criteria 
do not receive an ESA. 
The objectives of this study were two-fold. The first objective was to estimate the 
number of cancer patients in this province who meet guideline criteria, but yet fail to 
receive an ESA. Further to this, we sought to determine whether there are demographic 
factors associated with receiving an ESA. The second objective was to review the 
evidence around ESAs and their effect on tumor outcome and survival. 
In order to achieve these objectives, a retrospective review of 110 patients' 
medical records was undertaken. All patients with hematologic malignancies meeting the 
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2002 American Society of Clinical Oncology (ASCO)/American Society of Hematology 
(ASH) guidelines11 for receipt of an ESA during the period from January 2003 to 
December 2005 were included. 
1.3. Outline 
The first section of Chapter 2, the Literature Review, will begin with a review of 
the etiologies, prevalence and sequelae of cancer-related anemia. The next section will 
discuss the evidence for and safety concerns around the use ofESAs. Finally, a brief 
regulatory history of ESAs will be provided. 
Chapter 3, the Methods, will detail the study design, patient selection criteria and 
data collection and analysis. In Chapter 4 the results obtained from the chart review 
examining local ESA utilization will be presented and Chapter 5 will provide a literature 
review examining tumor progression and survival data from randomized controlled trials. 
Chapter 6, the Discussion, will review the implications of the results, the benefits 
and risks ofESAs, the study limitations and future directions. Finally, the study 
conclusions will be presented in Chapter 7. 
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Chapter 2: Review of Literature 
2.1. Anemia in Patients with Cancer 
Anemia, a deficiency in the concentration of hemoglobin-containing red blood 
cells, is a common problem in patients with cancer. There are several causes of cancer-
related anemia, including direct tumor infiltration of the bone marrow, blood loss, 
myelosuppression from radiation and cytotoxic chemotherapeutic agents and anemia of 
chronic disease. The latter of these, anemia of chronic disease, is one of the most 
common reasons for anemia in patients with malignancies and is characterized by 
activation of macrophages and a variety of cytokines, including Interferon-g, Interferon-I 
and tumor necrosis factor. These result in erythroid hypoplasia in the bone marrow, 
decreased red blood cell survival, disordered bone marrow utilization of iron and 
relatively low serum erythropoietin levels. 15-18 
The frequency of cancer-related anemia varies with the type of neoplasia and is 
very common in the hematologic malignancies. At diagnosis, 30 to 40% of patients with 
Hodgkin's lymphoma or non-Hodgkin' s lymphoma8 and 70% of patients with multiple 
myeloma 19 are anemic. The prevalence of anemia is even higher in the myelodysplastic 
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syndromes.20 The following is the anemia classification scheme used by National Cancer 
Institute in the United States?1 
Grade 0, within normal limits (hemoglobin 120 to 160 giL for women, 140 to 180 
giL for men) 
Grade 1, mild (hemoglobin 1 00 giL to normal limits) 
Grade 2, moderate (hemoglobin 80 to 99 giL) 
Grade 3, serious or severe (hemoglobin 65 to 79 giL) 
Grade 4, life threatening (hemoglobin less than 65 giL) 
Using this grading scheme, 74% of patients with non-Hodgkin's lymphoma have grade 3 
anemia while receiving CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisone). 22 
The effects of anemia vary widely depending on a number of factors, including 
the degree of anemia, the rapidity of onset and the presence or absence of comorbidities. 
Mild to moderate anemia may produce typical signs and symptoms like pallor, fatigue, 
shortness of breath, palpitations and tachycardia. More severe or chronic anemia, despite 
the body's attempt to counter-regulate, eventually affects nearly every body system; some 
of the effects include heart failure, pulmonary edema, depression and cognitive 
dysfunction. 1 
In addition to physical symptoms, anemia and the symptoms thereof, have been 
demonstrated to adversely affect quality of life in patients with cancer. Studies by Cella 
2
' 
3 
used validated subscales of the Functional Assessment of Cancer Therapy (FACT) 
questionnaire, the FACT-Anemia (FACT-An) and FACT-Fatigue (FACT-F) to assess 
outcomes in cancer-related anemia. In these studies, patients with hemoglobin levels less 
5 
than 120 giL reported significantly more fatigue, more non-fatigue anemia-related 
symptoms, poorer physical well-being, poorer functional well-being, decreased ability to 
work (beyond that related to fatigue) and poorer overall quality of life. 
There was some earlier evidence that anemia, and consequent tissue hypoxia, 
might reduce the efficacy of chemotherapy and radiation. 23 Additionally, severe anemia 
symptoms may necessitate reduced dosing or delays in the delivery of chemotherapy. 
These observations led to the hypothesis that cancer-related anemia may adversely affect 
disease control or survival. Recent clinical trials have not supported this hypothesis.9• 10 
Historically, allogeneic red blood cell transfusions have been the mainstay of 
treatment for severe anemia, while mild to moderate anemia was left untreated. While 
chronic anemia adversely affects multiple organ systems and quality of life, as described 
above, red blood cell transfusions are associated with a number of risks. Frequent 
transfusions are inconvenient for patients and place them at risk for transfusion reactions 
and infections. Most reactions, including febrile non-hemolytic transfusion reactions and 
minor allergic reactions, are mild. Approximately 800,000 units of red blood cells are 
transfused in Canada each year and the estimated numbers of serious adverse events for 
red blood cell transfusions are shown in Table L 1.4 Included in the lung injury category 
is transfusion-related acute lung injury (TRALI). TRALI is a syndrome characterized by 
the acute onset of noncardiogenic pulmonary edema following transfusion. It is 
associated with high morbidity with the majority of patients requiring ventilatory support. 
Due to better donor selection and screening, the infectious risks associated with 
transfusions have decreased substantially and TRALI is now the most common serious 
adverse event associated with red blood cell transfusions. 24 The exact incidence is 
6 
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unknown and estimates in the literature vary widely from 1 in 1,120 to 1 in 557,000 red 
blood cell units transfused.4 In addition to these risks, the blood supply represents a 
limited resource, which must be judiciously utilized. 
Table 2.1. Approximate Number of Serious Adverse Events Associated with Red 
Blood Cell Transfusions in Canada Each Year 
Adverse Event 
Lung Injury 
ABO Incompatible 
Bacterial Sepsis 
Hepatitis B Virus 
Hepatitis C Virus 
Human Immunodeficiency Virus 
Number per 800,000 Transfusions 
160 
20 
8 
4 
0.3 
0.2 
2.2. Use of Erythropoiesis-Stimulating Agents in Cancer-Related Anemia 
Human erythropoietin is a heavily glycosylated peptide hormone with165 amino 
acids and a molecular weight of 34 kDa. Approximately 90% of the body's 
erythropoietin is produced in the peri tubular interstitial cells of the kidney and 10% is 
produced elsewhere, including the liver. Erythropoietin is not stored and the stimulus for 
its production is decreased oxygen tension in the tissues. Erythropoietin stimulates 
erythropoiesis by increasing the number of committed progenitor cells. 
7 
Epoetin alfa (Eprex, Epogen, Procret) is a recombinant glycoprotein with an 
amino acid sequence identical to that of natural human erythropoietin 25. The United 
States Food and Drug Administration (FDA) frrst approved Epoetin alfa (Procrit®, Ortho 
Biotech, Bridgewater, NJ; Epogen®, Amgen; Eprex®, Janssen-Cilag Ltd, High 
Wycombe, U.K.) as a pharmaceutical in 1989 for anemia associated with chronic renal 
failure. Since that time there have been numerous studies into its potential use in the 
management of cancer-related anemia 
Presently, there are two other erythropoiesis-stimulating agents (ESAs) available: 
darbepoetin alfa (Aranesp®, Amgen, Thousand Oaks, CA) and epoetin beta 
(NeoRecormon®, Roche, Basel, Switzerland). Epoetin alfa and beta have the same 
amino acid sequence, but differ in their glycosylation patterns. Darbepoetin alfa differs 
from epoetin alfa and beta in its amino acid sequence and glycosylation pattern. These 
agents belong to the same pharmacologic class and are treated equivalently with respect 
to efficacy and safety by the ASH/ ASCO committee for the clinical practice guideline 
update on the use of epoetin and darbepoetin 12 and the FDA. 
Important considerations for the use of ESAs in the treatment of cancer-related 
anemia include their hematologic response, effect on transfusion requirements, effect on 
quality of life, safety profile and effect on disease outcomes and survival. The remainder 
of this section will discuss each of these issues separately. 
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2.2.1. Erythropoiesis-Stimulating Agents and Hematologic Outcomes 
Numerous clinical trials have examined the effect that ESAs have on hemoglobin 
concentration or hematocrit in patients with cancer. A multicenter double-blind placebo-
controlled trial involving patients with hematologic and solid malignancies with 
hemoglobin concentrations less than 105 giL randomized patients to receive recombinant 
human erythropoietin or placebo. 5 Hematologic response was measured in three ways: 
1) A rise in hematocrit level to 38% unrelated to transfusion, 2) An increase in hematocrit 
by at least 6% unrelated to transfusion, and 3) A change from baseline to fmal 
hematocrit. Using each of these measures, the group that received erythropoietin had a 
significant improvement in their hematocrit (p = 0.0001). 
In another study involving anemic cancer patients receiving cisplatin-based 
chemotherapy, the mean hematocrit increased by 6% over the three-month study period 
in patients who received recombinant erythropoietin 26• This was significantly greater 
than the 1.3% rise in hematocrit seen in the group that received placebo. 
In a recent review by the Cochrane Collaboration involving 22 trials and 4307 
participants, the relative risk (RR) of a hematologic response was 3.46 (95% confidence 
interval, CI 3.09 to 3.87).8 These results confirm that use ofESAs in anemic cancer 
patients does result in increased hemoglobin or hematocrit. 
9 
2.2.2. Erythropoiesis-Stimulating Agents and Transfusion Requirements 
Prior to ESAs, allogeneic red blood cell transfusion was the mainstay of treatment 
for anemia. Transfusions are associated with a mnnber of risks, ranging from minor 
febrile and allergic reactions to significant and life-threatening reactions like TRALI. 
While improved donor selection and screening have reduced the risk of infectious disease 
transmission, there exists a small, but finite risk. Finally, frequent transfusions are 
inconvenient for patients and place strain on a limited resource. 
There is good evidence that ESAs decrease transfusion requirements in patients 
with cancer-related anemia. For example, in a randomized, double-blind placebo-
controlled trial by Cascinu et al., patients undergoing chemotherapy with hemoglobin 
levels less than 90 giL were randomized to receive either recombinant human 
erythropoietin or saline. Over the course of the nine-week study period, 20% of patients 
in the erythropoietin arm required red cell transfusions versus 56% of patients in the 
placebo arm (p = 0.01)?7 
In a large cohort study involving patients with a variety of hematologic and solid 
malignancies in 34 centers across Canada, transfusion requirements decreased when 
patients were treated with epoetin alfa.6 In the cohort that was not receiving 
chemotherapy, 29% had received at least one red cell transfusion in the month before 
study initiation. After two months of epoetin alfa therapy, there was a significant 
decrease in the percentage of patients who required transfusion (196/o; p < 0.02). After 
four months of therapy, only 8% required transfusion (p < 0.001). The results were 
similar in the cohort that was undergoing chemotherapy. The number of patients 
10 
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requiring transfusion in that group decreased from 34% in the month prior to the study, to 
19% after two months on epoetin alfa therapy (p < 0.001), to 9% after four months of 
therapy (p < 0.0001). 
In 1997, the American Society of Clinical Oncology (ASCO) and the American 
Society of Hematology (ASH) submitted a proposal to the Agency for Healthcare 
Research and Quality (AHRQ) for a review of the use of recombinant erythropoietin in 
cancer patients. This proposal was accepted and the task was awarded to the Blue Cross 
and Blue Shield Association Technology Evaluation Center (TEC). The meta-analysis 
conducted by the TEC used randomized controlled trials that used subcutaneous epoetin 
alfa. This review, published in 2001, revealed a cumulative odds ratio of 0.38 (95% CI 
0.28 to 0.51 ), suggesting that the use of epoetin alfa reduces the relative odds of receiving 
a red blood cell transfusion by 62%.28 
The issue of transfusion requirements was reviewed by the Cochrane 
Collaboration.8 This meta-analysis involving 42 trials and 6510 patients found that the 
relative risk of receiving a red blood cell transfusion was reduced by 36% in study groups 
that received ESAs (RR 0.64, 95% CI 0.60 to 0.68). It is now well accepted that in 
patients with cancer-related anemia, ESAs decrease transfusion requirements. 
11 
.------------------------------------~-- -~ 
2.2.3. Effect of Erythropoiesis-Stimulating Agents on Quality of Life in Cancer 
Patients 
Anemia in cancer patients is associated with fatigue, poor physical and functional 
well being, decreased ability to work and poor overall quality of life.2' 3 ESAs have been 
shown to improve quality of life in patients with cancer-related anemia. 
In a large, non-randomized multicenter Canadian trial with anemic cancer 
patients, two quality of life measurement tools were utilized: the 1 00-mm linear analog 
scale assessment (LASA) and the FACT-An questionnaires.6 The LASA tool assessed 
three aspects of quality of life: energy level, daily activities and overall well-being. The 
baseline scores were indicative of poor quality of life on all three aspects. By the end of 
the 16-week study, all scores in the group receiving recombinant erythropoietin had 
increased significantly (p < 0.001). Interestingly, there was a difference in the mean 
LASA change between patients who had a hematologic response to erythropoietin and 
those who did not. There was a significant positive correlation between change in LASA 
and change in hemoglobin on all three measures: energy level (r = 0.30, p = 0.001), daily 
activities (r = 0.29, p = 0.002) and overall well-being (r = 0.25, p = 0.009). The daily 
activities and overall well-being scores actually decreased in patients who did not have a 
hematologic response to erythropoietin therapy. Scores on the FACT-An also 
significantly improved in patients receiving erythropoietin, but only in the group not 
receiving chemotherapy (p < 0.002). As with the LASA data, there was a marked 
difference in the end-of-study FACT-An scores between those who responded to 
erythropoietin therapy and those who did not. There was a significant positive 
12 
correlation between change in hemoglobin and change in FACT-An score (r = 0.33, p < 
0.001). 
More recent studies have focused on the benefit of early therapy with ESAs. A 
multicenter, randomized trial involving anemic patients starting chemotherapy for 
hematologic malignancies compared early versus late therapy with epoetin alfa.7 Patients 
with baseline hemoglobin concentrations of 100 to 120 giL were randomized to receive 
epoetin alfa immediately or to wait and receive it only if their hemoglobin concentration 
fell below 90 giL. Patients who received epoetin alfa early had significantly higher 
FACT-General (FACT-G), FACT-An and FACT-F scores, as well as higher scores on the 
physical and functional well-being subscales. The group randomized to early epoetin alfa 
therapy also had higher energy level, daily activity and important activity LASA scores, 
and had fewer bed-rest and restricted activity days. Importantly, clinically relevant 
thromboembolic events were more common in the group that received early therapy 
(11.1% and 3.0% in the early and late groups, respectively, p = 0.015). 
While there have been many studies looking at the question of whether quality of 
life in anemic cancer patients is improved with ESA therapy, the trials and methods of 
analysis used have been generally of lower quality. This question has not been 
definitively answered in a randomized controlled trial. In a recent review of this 
literature, 8 Bohlius states, "Taking the results together, the results show an overall 
positive effect on health-related quality of life from Epo which seems unlikely to be due 
to chance." 
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2.2.4. Risks Associated With the Use of Erythropoiesis-Stimulating Agents 
Recent concerns over the use of ESAs in patients with cancer have focused on 
two main aspects: 1) the risk of venous and arterial thromboembolic events, and 2) the 
effect on tumor outcomes and survival. The following examines the risk of 
thromboembolic events; new evidence around ESAs and tumor outcomes will follow in 
the subsequent section. 
There is evidence that ESAs increase thromboembolic risk. In patients with 
chronic kidney disease, this was demonstrated in the CHOIR trial. In the CHOIR study, 
29 1432 patients with chronic kidney disease were randomized to receive a dose of 
epoetin alfa targeted to achieve a hemoglobin level of 135 giL or a dose targeted to 
achieve a hemoglobin of 113 giL. The primary end point was a composite of death, 
myocardial infarction, hospitalization for congestive heart failure and stroke. 
Significantly more events occurred in the high-hemoglobin group (125) than in the low-
hemoglobin group (97; hazard ratio, HR 1.34, 95% CI 1.03 to 1. 74, p = 0.03) 
The Cochrane Collaboration reviewed the question of thromboembolic risk in 
cancer patients treated with ESAs in a meta-analysis. 8 In this analysis involving 35 trials 
and 6769 participants, the risk of thromboembolic events was increased in patients 
treated with ESAs by 67% (RR 1.67, 95% CI 1.35 to 2.06). Of these trials, 21 included 
patients with solid malignancies only, 7 included only patients with hematologic 
malignancies and 7 studies included both solid and hematologic. Trials involved study 
patients who were and were not receiving cancer chemotherapy. Importantly, the risk of 
thombosis varies with baseline risk. The Cochrane review addresses this issue by 
14 
calculating the numbers needed to harm (NNH) for several hypothetical baseline risks: 
We calculated numbers needed to harm for several hypothetical baseline risks. In 
a population with an underlying risk of 2% the NNH would be 74.63 (95% CI 
4 7.17 to 142.86), thus one thromboembolic complication would occur for every 
75 patients treated. In a population with an underlying risk of 5% the NNH would 
be 29.87 (95% CI 18.87 to 57.14), thus for every 30 patients treated with 
Epo/Darbepo one additional thromboembolic complication might happen. In a 
population with a hypothetical baseline risk of 10% the NNH would be 14.93 
(95% CI 9.43 to 28.57), thus for every 15 patients treated one additional 
thromboembolic complication may happen. These results show that the potential 
harmfulness ofEpo/Darbepo depends on the underlying risk for thromboembolic 
complications. 
2.2.5. Effect of Erythropoiesis-Stimulating Agents on Tumor Outcome and 
Survival 
Recent evidence has suggested that in addition to increased thrombotic risk, ESAs 
may adversely affect tumor outcomes and survivaL In vitro studies have demonstrated 
erythropoietin receptor expression in numerous tumor cell lines including breast, cervical, 
endometrial, papillary thyroid, non-small cell lung, squamous head and neck cancers and 
melanoma. 30 There is also evidence that endothelial cells have large numbers of 
erythropoietin receptors and that erythropoietin enhances their proliferation and 
. . 31 32 
mtgratlon. ' 
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Several large clinical trials have recently demonstrated that ESAs may have a 
deleterious effect on survival in patients with cancer, including the BEST9 and EPO-
CAN-2033 trials. Other studies have demonstrated variable effects on disease control. 
Studies showing poorer tumor outcomes include ENHANCE10and DAHANCA-10.34 In 
both these trials, however, the majority of patients were not anemic. A recent meta-
analysis examining the effect ofESAs on tumor outcomes and survival35 found a 
significantly reduced risk of rapidly progressive disease for patients treated with epoetin 
beta (RR 0.78, 95% CI: 0.62, 0.99; P = 0.042). 
Unlike the circumstance in which cancer patients are undergoing chemotherapy, 
there is reasonable evidence to suggest that ESAs not be used in cancer patients who are 
not undergoing chemotherapy. There is evidence for their use in patients with 
myelodysp1asia36· 37 but not in patients with other malignancies who are not undergoing 
chemotherapy. A large trial examining the issue of tumor outcome and survival in cancer 
patients not undergoing chemotherapy or radiation was the Danish Head and Neck 
Cancer Group (DAHANCA) 10 study.34 This study revealed a higher mortality in 
patients treated with darbepoetin alfa. The results of the DAHANCA trial led to an FDA 
alert in February 2007 that raised concerns about the potential adverse effects of ESAs in 
anemic cancer patients who are not receiving chemotherapy. A subsequent trial in 
patients not undergoing chemotherapy33 showed that survival was significantly lower in 
patients receiving epoetin alfa compared with the placebo. The largest of the trials to 
demonstrate reduced survival with ESAs in cancer patients not undergoing chemotherapy 
was Amgen Study 20010103.38 The Clinical Study Report submitted to the FDA in 
March 2007 described a survival disadvantage in patients receiving darepoetin and led to 
16 
an added black box warning to epoetin alfa and darbepoetin in March 2007 stating that 
ESAs are not indicated for patients with cancer who are not receiving either 
chemotherapy or radiation. This stance is also held by the ASH/ ASCO committee for the 
clinical practice update on the use of ESAs. 
In summary, several randomized controlled trials have suggested an adverse 
effect on survival in cancer patients receiving ESAs. The evidence in this area is strong 
for patients who are not receiving chemotherapy but considerably weaker for patients 
who are. Specifically, many of these trials used ESAs in patients who were not anemic 
and their hemoglobins were raised to high targets. Additional well-designed randomized 
controlled trials in anemic cancer patients receiving chemotherapy are required to further 
elucidate their effects on tumor outcomes and survival in this patient population. These 
studies are reviewed in detail in Chapter 5. 
The above discussion detailed the current state of the evidence for the benefits 
and risks of ESAs in patients with cancer-related anemia. In conclusion, there is 
substantial evidence that ESAs improve hemoglobin or hematocrit levels and decrease 
transfusions in anemic cancer patients. Anemia is associated with decreased quality of 
life in patients with cancer and it is likely that ESAs improve this. Additional well-
designed studies are required to more definitively address this issue. ESAs do increase 
the risk of thromboembolic disease in several patient populations and the relative increase 
is related to underlying risk of thromboembolic disease. Recent trials have suggested 
poorer tumor outcomes and survival in cancer patients treated with ESAs. Many of these 
trials suffer from methodological flaws and further studies are needed. 
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2.3. Regulatory History of Erythropoiesis-Stimulating Agents 
The first ESA approved by the FDA, Epoetin alfa, was licensed on June 1, 1989 
and was indicated for the treatment of anemia associated with chronic kidney disease, 
both for patients with end stage kidney disease and those not on dialysis. Subsequently it 
was approved for anemia associated with zidovudine therapy in patients with AIDS in 
1991, cancer-related anemia in 1993 and for pre-surgical administration in order to 
reduce perioperative transfusion requirements in 1996. 
Since that time, changes to the label have included: a warning regarding higher 
mortality in patients with chronic renal failure with treatment regimens intended to 
maintain a hemoglobin level of 120 to 140 giL in 1996, information regarding effects on 
response rate, time to progression, and overall survival in solid tumors in May 2004 
following the ODAC meeting, a new dosing regimen (40,000 U/kg weekly) for the 
treatment of anemia associated with cancer chemotherapy in June 2004 and new 
information regarding pure red cell aplasia in October 2005. In March 2007, a warning 
was added about the risk of poorer survival in cancer patients not undergoing 
chemotherapy. 
Darbepoetin alfa was first licensed in September 2001 for the treatment of anemia 
associated with chronic kidney disease, including patients on and not on dialysis. The 
license was expanded in Ju1y 2002 to include chemotherapy-associated anemia in cancer 
patients. Changes to the label for darbepoetin alfa have included: a new dosing regimen 
( 40,000 U/kg weekly) for the treatment of anemia associated with cancer chemotherapy 
in June 2004, information about the effects on thrombotic events and tumor promotion in 
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December 2004 and new information regarding pure red cell aplasia in October 2005. In 
March 2007 the warning about decreased survival in cancer patients not undergoing 
chemotherapy was added. 
All of the ESAs currently licensed are considered to belong to the same 
pharmacologic class and are treated equivalently by the FDA with respect to safety 
issues. In November 2007, the warnings about ESAs in cancer patients were 
strengthened as a result of the newest studies showing more rapid twnor growth and 
shortening survival. In February 2008, the FDA approved a revised label for ESAs 
including the updated boxed warning stating that ESAs "shortened overall survival and/or 
time-to-twnor progression in clinical studies in patients with breast, non-small-celllung, 
head and neck, lymphoid, and cervical cancers, when dosed to target hemoglobin of 
greater than or equal to 12 grams per d/1." 
In summary, cancer-related anemia is multifactorial with the most common 
causes being chemotherapy-associated anemia and cytokine-mediated anemia of chronic 
disease. Anemia is very common in patients with hemologic and solid cancers and is 
associated with significant physical morbidity and decreased quality of life. Historically 
red blood cell transfusions were the mainstay of therapy for cancer-related anemia. 
Frequent transfusions have associated risks including a variety of transfusion-related 
reactions and infectious disease transmission. ESAs are a group of pharmaceuticals made 
with recombinant DNA technology that are identical or similar to human erythropoietin. 
ESAs have been shown to raise hemoglobin or hematocrit and decrease transfusion 
requirements in patients with cancer-related anemia. They may improve quality of life. 
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ESAs increase the risk of thromboembolic events and may adversely affect disease 
outcomes or survival, particularly in patients not undergoing chemotherapy. The FDA 
has recently strengthened its warnings about the use of ESAs in cancer patients. This is 
presently an area of very active research. 
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Chapter 3: Methods 
3.1. Study Design 
Guidelines from the American Society of Clinical Oncology (ASCO) and the 
American Society of Hematology (ASH) regarding the use ofESAs in patients with 
cancer exist 11 • The first o~jective of this study was to determine the number of patients 
in Newfoundland and Labrador who meet guideline criteria to receive ESAs and actually 
do receive one. Associated with this objective, we sought to determine whether there 
were demographic factors associated with receipt of an ESA. The second objective was 
to review the randomized trial data on ESA use in patients with malignancies. 
In order to accomplish the first objective a retrospective design was used in which 
data were obtained from patients' medical records. Ethical approval for the study was 
obtained through the Human Investigation Committee (HI C) at Memorial University, St. 
John's, Newfoundland and Labrador on February 16,2006 (Appendix A). The 
Research Proposals Approvals Committee (RP AC) of Eastern Health approved the study 
on June 13, 2006 (Appendix B). 
Patients with hematologic malignancies meeting ASCO/ ASH criteria for 
receiving ESAs were selected for the study. Specifically, patients with diagnoses of 
multiple myeloma, non-Hodgkin' s lymphoma or chronic lymphocytic leukemia 
undergoing chemotherapy with a hemoglobin concentration of less than 100 giL were 
included. As well, in accordance with the guidelines, patients with myelodysplasia (not 
receiving chemotherapy) and hemoglobin concentrations less than 100 giL were 
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included. As these guidelines were published in October 2002, it was assumed that 
several months would be required for these to translate into clinical practice. Hence, the 
period from which data were collected began in January 2003. The data collection period 
was three years long and ended in December 2005. Patients eligible for the study were 
identified according to the above criteria through the Medical Records Department at the 
Health Sciences Centre, St. John's. Data were collected from patients' electronic medical 
records on the MEDITECH system (Medical Information Technology, Inc., Westwood, 
MA) in August 2007. 
3.2. Patient Selection 
Patients were included in the study if they met the ASCO/ ASH guidelines for 
receiving an ESA. Specifically, the inclusion criteria for the study required that patients 
had a diagnosis of multiple myeloma, non-Hodgkin' s lymphoma or chronic lymphocytic 
leukemia and received chemotherapy, or had a diagnosis of myelodysplasia, during the 
period of January 1, 2003 to December 31 , 2005. In accordance with ASCO/ASH 
guidelines for receipt of an ESA, patients had to be anemic with a hemoglobin 
concentration of 1 00 giL or less. All male and female patients meeting the study criteria 
from all areas of Newfoundland and Labrador were included. 
Patients were excluded if their hemoglobin concentration was very transiently 
below 100 giL or if it was evident that their anemia was clearly secondary to another 
etiology, for example, gastrointestinal or postoperative bleeding. Data were collected on 
all eligible patients (110 in total). 
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3.3. Data Collection 
Data were collected on all 110 patients meeting the study inclusion criteria The 
same individual collected all data and the data extraction method was the same for all 
patients. Although the entire data collection period spanned three years, for an individual 
patient, the "study period" was defined as the period of time during which the patient met 
guideline criteria for receiving an ESA. For patients with multiple myeloma, non-
Hodgkin's lymphoma and chronic lymphocytic leukemia, the study period began at the 
start of chemotherapy. For patients with myelodysplasia, the study period began either 
when the diagnosis was made or at the beginning of the data collection period, January 1, 
2003. An individual patient's study period ended when one of the following occurred: 1) 
the chemotherapy regimen was finished and a one-month follow-up period during which 
the chemotherapy was likely to be contributing to the patient's anemia was over, 2) the 
three-year data collection period ended, 3) the patient was lost to follow-up or 4) the 
patient died. Information obtained included the patients' age, diagnosis, start and 
completion dates of chemotherapy, hemoglobin measurements obtained during the 
patients' individual study periods as defined above, whether or not patients received an 
ESA during their study period, the number of red blood cell transfusions patients received 
during their study period and whether their place of residence was urban or rural (based 
on the patients' postal codes). As it was collected, data were entered into an SPSS (SPSS 
Inc, Chicago, II) data file. 
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3.4. Data Analysis 
Data analysis was completed using SPSS statistical software. The number of 
patients receiving an ESA was calculated using the descriptive statistics function. In 
addition to the primary outcome, the patients' average hemoglobin concentrations and 
percentage of time spent with hemoglobin concentrations less than 100 giL were 
calculated. Because patients were followed for variable durations of time and because 
hemoglobin concentrations were measured at variable intervals (for example, blood work 
may have been done daily if a patient was admitted during their study period versus prior 
to every cycle of outpatient chemotherapy), these measurements had to be standardized 
for the purpose of analysis. This was done by calculating an average weekly hemoglobin 
for each study week for each patient. If a patient had multiple hemoglobin measurements 
for a given week, then the average of these values was determined. If a period of time 
elapsed without a hemoglobin measurement, then a weekly value (or several weekly 
values, as necessary) was estimated by taking the mean of preceding and succeeding 
measurements. These values were then used to calculate the patients' average 
hemoglobin concentration over the total number of study weeks as well as the percentage 
of time spent with hemoglobin concentrations less than 100 giL. The number of red 
blood cell transfusions received was also calculated. 
The demographic features associated with receipt of an ESA were calculated 
using an independent samples t-test and chi-squared test to determine whether there was a 
relationship between the primary outcome and age and place of residence, respectively. 
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These were calculated using the descriptive statistics functions using SPSS. For these 
tests statistical significance was taken to be less than 0.05. 
3.5. Literature Review 
A search of PubMed and EMBASE was conducted by combining the following 
the MeSH terms: erythropoietin; erythropoietin, recombinant, darbepoetin, anemia and 
cancer. In addition, the 2007 ASH annual meeting abstracts, FDA reports and reference 
lists of clinical trials and systematic reviews were searched for relevant articles. 
Randomized controlled trials were included in this review. 
25 
Chapter 4: Results 
4.1. The Number of Patients Receiving an Erythropoiesis-Stimulating Agent 
Patients with hematologic malignancies meeting the 2002 ASCO/ ASH criteria for 
receiving an ESA during the study period were identified. A total of 110 patients met 
these criteria and their medical records were reviewed. Anemic patients (with 
hemoglobin concentrations less than 100 giL) with diagnoses of multiple myeloma, non-
Hodgkin' s lymphoma or chronic lymphocytic leukemia undergoing chemotherapy and 
patients with myelodysplasia (not receiving chemotherapy) were included. The 
distribution of study patients with each ofthese diagnoses is shown in Figure 4.1.1 . 
40 
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Figure 4.1.1. Distribution of Study Patients' Diagnoses 
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The primary goal of this study was to determine the nwnber of patients in 
Newfoundland and Labrador meeting guideline criteria for receiving an ESA that actually 
do receive these drugs. For this population of 110 patients, only 16.4% actually received 
the ESA, epoetin alfa (Eprex). This result is shown in Figure 4.1.2. 
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Figure 4.1.2. Proportion of Study Patients Receiving Erythropoietin 
The extent of anemia in this patient sample was measured in three ways: I) the 
overall mean weekly hemoglobin concentration, 2) the proportion of time that the study 
patients' hemoglobin was less than 100 giL and 3) the number of red blood cell 
transfusions patients received. 
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The overall mean weekly hemoglobin concentration for this study population was 
89.1 giL (standard deviation, SD, 19.4 giL). This result was calculated using the 
transformed average weekly hemoglobin concentration and the total number of study 
weeks (2376). Clearly, this average hemoglobin is much lower than the hemoglobin at 
which the current guidelines reconm1end the use of an ESA. The SPSS output file 
yielding this result, along with the median and mode hemoglobin concentrations and 
quartiles is shown in Table 4.1.1. 
Table 4.1.1. Overall can 'cc 'y Hcmog o in Concentration 
Hb extrapolated 
V ahd 237 
Miss1ng 0 
Mean 9.11 99 
Med1an 8 .0000 
Mode .00 
Std. evia 1on 
Percentiles 2~ .0000 
c: o 
.0000 
c: 99.0000 ~ 
The second way in which the extent of anemia was measured was with the 
proportion of time the patients spent with a hemoglobin concentration that was less than 
100 giL. This result is shown in Table 4.1.2. 
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Table 4.1.2. Proportion of Time Hemoglobin Concentration was Less Than 100 giL 
V sl i o S..:l~c:t:-o 
5-: l ~ c:t~ 
Tots l 0 0 
It can be seen from Table 4.1.2, that for 75.3% ofthe study weeks, the patients' 
hemoglobin concentrations were less than 1 00 giL. This indicates that the patients spent 
three quarters of the study weeks with hemoglobin concentrations less than that required 
to receive an ESA according to guidelines. 
The third way in which this study sought to characterize the extent of anemia in 
this study population was by determining the number of transfusions that patients 
received. In these 110 patients, 781 red blood cell transfusions were administered over 
the study weeks. With a total of 23 7 6 study weeks, patients received an average of 0.3 3 
transfusions per week, in other words approximately one transfusion every three weeks. 
There were an average of 7.1 transfusions per patient per study period. 
In summary, the medical records of all 11 0 patients with diagnoses of multiple 
myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia or myelodysplasia 
that met the ASCO/ ASH 2002 guidelines for receiving an ESA were reviewed. The 
majority of these patients had non-Hodgkin's lymphoma; chronic lymphocytic leukemia 
was the most infrequent diagnosis. Of the 110 study patients, only 16.4% received an 
ESA during the study period. These patients had moderate anemia, as the overall mean 
\.Veekly hemoglobin concentration was 89.1 giL. For 75.3% of the study weeks, the 
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patients' hemoglobin concentrations were under 100 giL. Patients were transfused an 
average of 7.1 times throughout their study period, with an average of one red cell 
transfusion every three weeks. 
4.2. Erythropoiesis-Stimulating Agents and Demographic Factors 
In this study, the effect of two demographic factors on receiving an ESA was 
examined: age and place of residence. An independent-samples t-test was conducted to 
determine whether there was any difference in the ages of the patients that received an 
ESA and those who did not. The SPSS output file for this test is shown in Table 4.2.1. 
Table 4.2.1. Comparison of Patient Age in the Groups Receiving and Not 
Receiving an ESA 
Group Statistics 
Std Encr 
Did tJ'I : pt retei\IE eoo" N M;;an Std O~;viauon Mean 
Ag;; ye-s 18 729<0 11 '-1)9 2 es9 
No 92 70 12 10 ~28 1 087 
Independent Samples Test 
Levene's Test for 
Equality of Vanances 1-lest for Equality of 1.\eans 
95% Confidence 
Interval of the 
1.\ean Std. Error Difference 
F SIQ. I df SIQ. l2-talierl) Difference Difference Lower Upper 
llge Equal vanances 
.4SO .504 1.035 108 303 2.82~ 2.729 -2.~84 8.234 assurnerl 
Equal vanances 
.974 22.897 340 2 825 2.901 -3.177 8827 
not nsumerl 
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As shown in Table 4.2.1, the mean age in the group receiving an ESA was 72.9 years (SD 
11.4) versus 70.1 years (SD 10.4 ). There was no significant difference between the ages 
of the patients in these groups (p = 0.3). This is shown graphically in Figure 4.2.1. 
80 -
0 -
-
20 -
0 I I 
yes No 
Did the pt receive epo? 
Figure 4.2.1. Patient Age in the Groups Receiving and Not Receiving ESA 
The second demographic factor that was investigated was place of residence. A 
chi-squared test was performed to determine whether there was a difference in the 
number of patients receiving an ESA from urban and rural areas of the province. More 
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patients from urban areas (61.1%) than rural areas (38.9%) received an ESA (X2 = 3.997, 
p = 0.046). The output file is shown in Table 4.2.2 and the corresponding graph in Figure 
4.2.2. 
Table 4.2.2. Comparison of Place of Residence in the Groups Receiving and Not 
Receiving an ESA 
Residence.1 • Did the pt receive epo? Crosstabu lation 
Residence.1 Urban Count 
Expected Count 
% 'l lth tn Restdence.1 
% 'llthin id the pt 
0.0% receive epo? 
% of - otal 
Rural Count 66 
Expected Count 10.8 cc ~.o 
% •1 ith1n Restd ence.1 10.6% 89. % 100.0% 
% 'l lthin td the pt 
38.9% .1% 60.0% receive epo? 
% o - otal 6. % 53.6% 60.0% 
- otal Count 1 92 110 
E pected Count 18.0 92.0 110.0 
% 'l ithin Restdence.1 . % 3. % 100.0% 
% w ithin td the pt 
100.0% 100.0% 100.0% receive epo? 
% of - otal 16. % 83.6% 100.0% 
Chi-Square Test s 
Pearson Cht-Square 
Cont~nuity Correctto" 
Li elihood Ratto 
Ftsher's E act est 
V alue 
3.997J 
3.01 
3.9 1C 
r of V ahd Cases 1·1 0 
a. Computed only for a 2x2 table 
df 
symp. Stg. Exact Sig. Exact Sig. 
12-s tded) 2-sided) (1-sided) 
.0 
.083 
.0 8 
.06 .0 2 
b. 0 cells (.0%) have e pected count less than c _ he mtnimum expected count ts 7. 
20. 
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Figure 4.2.2. Place of Residence in the Patients Receiving and Not Receiving an ESA 
The secondary objective of this study was to determine whether there were 
demographic factors associated with receipt of an ESA. Two demographic factors were 
considered: age and place of residence. It was determined that there was no difference 
between the age of the groups receiving and not receiving an ESA, however significantly 
more patients from urban areas of the province received an ESA than those from rural 
areas. 
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In summary, in this sample of patients meeting the ASCO/ ASH criteria to receive 
an ESA in Newfoundland and Labrador, 16.4% of patients received one. The study 
patients had moderate anemia, with an average weekly hemoglobin of 89.1 giL overall. 
For three quarters of the study period, the patients had hemoglobin concentrations of less 
than 1 00 giL and they received an average of one red blood cell transfusion every three 
weeks. T e average age was not different between the patients receiving and not 
receiving an ES~ however more patients from urban areas of the pro ·ince received an 
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Chapter 5: Effect of Erythropoiesis-Stimulating Agents on Tu or 0 teo e and 
Survival: A Literature Review 
There i ub tantial evidence that ESAs improve hemoglobin concentrations, 
decrease transfusion requirements and likely impro e quality of life in anemic cancer 
patients. However, recently there has been increasing attention t the safety of ESAs in 
this patient population. Numerou randomized controlled trial publi hed in peer-
reviewed journals have examined disease control and urvival in patients receiving SAs. 
T ere have a Rr me recent meta-analyses of these trials. ) The following is a 
review of the randomized trial data concerning tumor outcome an urvival in anemic 
eanccr patients receiving ESAs. Table 5.1 provi es a summary of the trials inc udcd in 
t..h..is review. 
A number of recent randomized contr lied trial rJ3 c dem n tratcd p er tumor 
ouLome:s or _urvival in patients with an er-• iated anemia receivin2 ~ S s. n the 
..,..,<:'T • 9 
•• t nJ. tria ' asc 1n ontr a , 9 9 patient with metastatic breast cancer undergoing 
first.- inc chcmot rapy wcr ran m1zc to receive cpoctin a fa 0 units wee · y or 
dy. t: /L.r po: fn was 1niti..,te w en e em 0 
lY . le prin1aa; endpo;nt was 12-lHOll 1 ovcwH su1 viva!. tJl.;Olll itl.:U1t ~.: 1ro oictin 
ear y in a cordance wi 
n cpe dent Data onitoring C' mmittcc 'cause t ere was a 
ln."aimcnt ._'r ur t t en ' of t <' rvival wru 70% i!1 
ihc epoelin alfa gr up anu 76% in l e pace ) group (p 0. i ) T 1 ~r ·-. ct. no ~.' :rr n: ;;.:e 
wo groups and ihr 
reason for the survival difference could not be established. The ENHANCE trial was a 
multicenter double-blind randomized placebo-controlled trial in patients undergoing 
radiotherapy for head and neck cancer. 10 This trial was designed to investigate whether 
anemia correction with epoetin beta could improve tumor outcome. In this study 351 
patients were randomized to receive epoetin beta 300 units/kg three times weekly or 
ptaccbo from days 0 to 4 before and continuing throughout radiotherapy. Locoregional 
progression-free survival was poorer in the cpoctin beta group than in e pace o group 
(adjusted rc tivc risk .62, 5% C .22 to 2. 4, p- 0.0008). The majority (82%) o 
patients treated with epoetin beta had hemoo o in concentrations greater 1 an 40 ;/L 
(women, or 50 n (men) compared \vith 15% treated "With place o. The results ofthc 
BEST a...~d E IA.NCE trials, along with study ~9 00 ]9 ( ... iscusse t • .e!o·;;) ·.vC"rc 
rn.crnbcrs of the ODAC agreed thnt the !C'snlts ofL~sc trials mi-:c com·cm:; t at r!'t;ni:-f'" . 
furth r <m1 ; 
In the EPO-CAN-20 triaJ·B, patients with advanced non-sma I eel ung cancer 
were g1v~ "'it ~r cport1n a fa or placebo to achieve a hemoglobin concentration of 120 to 
oetin alfa (median survival 63 versu~ 1...,0 
.~ays; HR, 1.84; P -= .04). 
T n ;;.dcition to t. c rruLom ·zed controlled trials published in peer-reviewed. jolDllais 
discussed above, several oth r Rtudi "Shave cxamineo t c effc•t c,l" ."" ~ • n m0r 
f224 patients with sm ce I mg cancer un crgo"ng trc~ tmen1 ·vii c. "me i ·mp:· i oo 
'I-. 
_:\_ : 
radiation. Patients received either Epogen at 40,000 IU/kg weekly or placebo and Epogen 
was withheld if the hemoglobin increased above 160 giL. The objective ofthis study was 
to exclude a 15% reduction in overall response rates. This study met its objective with an 
observed 6% difference in response rate between the two groups (95% CI -6% to 18%). 
No significant difference in overall survival was detected HR. 1.17 (95% CI~ 0.89, 1.55). 
Study 20000161 40 was a randomized, double-blind placebo-controlled study of Aranesp 
in anemic patients with lymphoproliferative malignancies. In this study, 344 patients 
undergoing chemotherapy were ra1'1domized to receive either Aranesp to achieve a target 
hemoglobin of 150 giL (men) or 140 giL (women) or placebo. Overall survival was 
shorter in the group who received Aranesp (HR 1.37; 95% CI 1.02, 1.83). The 
DAHANCA 10 study 34 was a randomized controlled trial of darbcpcctin in Ftient:; 
urn.:.ergnh~g rn.diot.'1erapy for head and neck cancer. The interim an~ysi~ '-Va$ m~de 
U"''"'ailuble online and sho\ved poorer outcomes L~ the group treatc vvit dar uCpc~tin fer 
the primary end point of locorcgional failure. 
With the exception ofmyelodysp1asia,3r,' 37 there is no evidence to support ESA 
usc for the treatment of cancer-associated anemia in patients not undergoing 
chemotherapy. This is reflected in the ASH/ ASCO guidelines. 1 1• 12 Arnrren study 
ind tria of darbepoetin versus placebo in 989 
patients -,.vith cancer not undergoing chemotherapy of myc c:;upprc:;i.vc ;-.:-tintrmL Th~:; 
t:-: ~~ -;, mvd thnt n·:cr:-H r:llTv1vn1 ·.vn~ poorer in the darbepoctin than in the control am: 
(HR 1_ 0; 95% CT 1.07 to 1.57; p - 0.00&). 
T ~ <p e~tion ofsurviva was addressed in a 2006 Cochrane Review.8 A meta-
analysis of 42 trials involving 8, 67 patients • s con ct ; "~ trl<ot (,' • r 1• r co.o i , 
-------~~~------------------------------------~--~~----~~~------~-
tumors only, 8 studies included hematologic malignancies only, 8 studies included both 
solid and hematological malignancies and one study involved patients with MDS. In 29 
studies, patients were undergoing chemotherapy, in 8 trials patients were undergoing 
radiotherapy or radiochemotherapy, and in two studies the treatment was categorized as 
unclear. Three studies involved patients not undergoing chemotherapy or radiation. In 20 
studies, the average baseline hemoglobin was below 1 00 giL, in 8 studies the average 
baseline hemoglobin was between 100 and 120 giL, in 7 studies the baseline hemoglobin 
was above 120 giL, and in 7 studies the hemoglobin at baseline was not reported. Results 
were taken from full text publications for 12 studies, unpublished data for 5 studies 
unpublished and abstracts for 3 studies. For 22 studies data were taken from FDA 
documents~ of those, 8 were exclusively published in FDA documents. This meta-
analysis revealed a hazard ratio of 1.08 (HR 1.08; 95% CI 0. 99 to 1.18) in favor of 
placebo or no treatment over treatment with an ESA. There was little heterogeneity 
between the trials (chi-square- 44.04; df- 39~ p _, 0.27; P ___, 11.5%) and funnel plot 
analysis did not suggest asymmetry (p- 0.35). 
The same Cochrane Review8 analyzed 13 trials with data about tumor response. 
Nine trials included only solid tumors, 3 studies included only hematologic malignancies 
!1nd 1 ~ti.!dy in:lude!.! _oth :;.~lid and hematologic tumors. In 4 studies patients received 
either radiotherapy or radiochemotherapy and in 9 studies patients received 
c cmotherapy. The average baseline hemoglobin was below 100 giL in 5 ~tudic:;, 
etween 100 and 120 giL in 4 studies, greater than 120 g!I. in_ studies and not report _ 
in stu_ y. This meta-analysis showed a relative risk of 1.12 (RR 1.12; 9 5% CI 1. 01 to 
1.2 ) in favor of erythropoietin.. There was marked heterogeneity (chi-square- 25. 4; d.f 
_It 
r 
= 14; p = 0.03; P=45.8%) and funnel plot analysis suggested some asymmetry (p = 0.03). 
The majority of these trials were not adequately powered to detect a difference in tumor 
response and those that were, were available only in abstract form or in documents 
submitted to the FDA ODAC meeting. The conclusion was that the effect of ESAs on 
tumor response could not be reliably assessed based on the available data. 
Another recent meta-analysis35 included 9 randomized studies of epoetin beta or 
placebo. There were a total of 1413 patients, 56% of which had hematological and 44% 
of which had solid malignancies. The average baseline hemoglobin in these studies was 
99 giL and the average maximum hemoglobin during treatment was 126 giL with epoetin 
beta and 116 giL with control. Overall survival during the first six months was similar 
with epoetin beta and control (0.31 versus 0.32 deaths per patient-year). No increased 
mortality risk was seen with epoetin beta (RR 0.97; 95% CI 0.69 to 1.36; p = 0.87). There 
was a significantly reduced risk of rapidly progressive disease with epoetin beta (RR 
0.78; 95% CI 0.62 to 0.99; p = 0.042). 
In summary, it remains unclear whether ESAs affect tumor progression or 
survival in patients with cancer-related anemia In the meta-analyses discussed above 
(both published in 2006) no significant differences in mortality were observed. The 
conclusion from the Cochrane Review8 was that the effect of ESAs on tumor response 
could not be adequately assessed given the quality of the available data The Aapro et 
al35 review found a reduced risk of rapidly progressive disease, however with only 9 
studies, there was clearly missing data. Consistent problems with the majority of 
available data have been the high baseline hemoglobin concentrations and target 
hemoglobin concentrations greater than 120 giL. Some of the trials reviewed above 
39 
- -----------------------
included patients not undergoing chemotherapy. The effect ofESAs, titrated to maintain 
a hemoglobin concentration near 120 giL, on a population of patients with cancer-related 
anemia undergoing chemotherapy is still unknown. 
Table 5.1. Randomized Trials of Erythropoietin 
Author, Year Tumour Response Overall Survival 
Abels, 199341 X 
Bamias, 20034 j X X 
Boogaerts, 
200344 
X 
Cascinu, X X 
199427 
Case, 1993' X 
Cazzola, X X 
199545 
Chan~, X 
2005 6 
Darnmacco, X X 
2001 47 
Deal X 
Mastro, 
199748 
Dunphy X 
199949 
EPOCAN- X 
1550 
EPOCAN- X 
2051 
EPOGBR- X X 
752 
GOG-019I'j X 
Hedenus, X 
200254 
Hedenus, X 
2003 10 
Henke, X 
2003 10 
Henr~, X 
1995 6 
INT-I" X 
40 
INT-3:><> X 
Kotasek, X 
200357 
Kurz, 1997''6 X 
Leyland- X X 
Jones, 
20039 
Littlewood, X 
2001 59 
Machtay, 
200460 
X X 
N93 004° 1 X X 
0' Shaugnessy, X 
200562 
Oberhoff, X 
199863 
Osterborg, X 
199664 
Osterborg, X X 
200265 
Overgaard34 X 
P-17466 X 
Razzouk, X 
200467 
Rose, 1994 6'6 X 
Savonije, 
200669 
X 
Smith, X 
200370 
Ten X X 
Bokkel, 
199871 
Thatcher, X 
199972 
Thompson, X 
20007 
Throuvalas, X X 
200074 
Vadhan- X X 
Raj , 200475 
V ansteenkiste, X 
200276 
Witzi , 
200579 X 
Wright, 200733 X 
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Chapter 6: Discussion 
6.1. Discussion of Results 
The purpose of this study was to 1) Examine the practice in Newfoundland and 
Labrador with respect to ESA use in patients with hematologic cancers and 2) To review 
the current state of the literature around tumor outcome and survival for cancer patients 
receiving ESAs. A number of organizations, including the Canadian Cancer and Anemia 
Guidelines Development Group (CCAGDG) 13, the European Organization for Research 
and Treatment of Cancer (EORTC) 14 and ASCO and ASH together 11 developed 
guidelines for the use ofESAs in patients with cancer. Despite the existence of these 
guidelines it has been the experience of the hematologists and medical oncologists in this 
province that patients with cancer-related anemia are not receiving ESAs. 
The first objective of this study was to estimate the number of patients with 
hematologic cancers in this province that meet ASCO/ ASH guidelines for receiving 
ESAs that actually do and do not receive these medications. A related objective was to 
determine whether there are demographic factors associated with receipt of an ESA. To 
accomplish these goals, the charts of patients with diagnoses of multiple myelom~ non-
Hodgkin's lymphoma, chronic lymphocytic leukemia and myelodysplasia between 2003 
and 2005 were reviewed. For patients with the first three of these diagnoses, only those 
undergoing chemotherapy are candidates to receive an ESA according to ASCO/ ASH 
guidelines and so only this group was included. All anemic patients with myelodysplasia 
were eligible. 
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Ofthe 110 charts reviewed, the majority of patients had non-Hodgkin's 
lymphoma; chronic lymphocytic leukemia was the least frequent diagnosis. Despite all 
of the study patients meeting guideline criteria for receiving an ESA, only 16.4% of them 
actually did receive one. A number of possibilities may explain this fmding: 1) these 
drugs are quite expensive and coverage provided by the provincial drug program is 
limited, 2) new literature suggests that there are significant adverse effects for cancer 
patients treated with ESAs which may have affected physicians' clinical decision making, 
and 3) other factors, like patient demographics, may have played a role. 
ESAs are very costly. For example, for the recommended dose of Eprex of 150 
Ulk:g three times weekly, for a 70 kg person, the weekly cost ofEprex is approximately 
$450.00. Medications considered for coverage under the Newfoundland and Labrador 
Prescription Drug Program (NLPDP) are reviewed by an Expert Advisory Committee 
(EAC) representing the four Atlantic provinces. In March 2006, the following criteria 
were put forth by the EAC: 
Coverage of Eprex is considered under Special Authorization for: 
The treatment of anemia in hematological malignancy in transfusion dependent 
patients with a baseline Hgb ~ 90 giL whose transfusion requirements are 2::: 2 
units of packed red blood cells (PRBC/month) over a 3 month period. An initial 
trial of 12 weeks with documentation of dose, Hgb and therapeutic outcome ( # of 
transfusions) [is required]. 
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Further 12 week cycles can be approved dependent on evidence of clinical 
response or reduced treatment requirements to < 2 units of PRBC/month. If 
transfusion requirements increase to ~ 2 units/month (over a 3 month period), 
one dose increase may be attempted (maximum dose 60,000 iu per week) 78. 
Given the high cost of ESAs, many patients are unable to afford these drugs without 
some form of subsidy. These recommendations, which have been adopted by the 
NLPDP, clearly prohibit many patients from receiving any government subsidy toward 
the cost of these drugs. Importantly, they are out of keeping with the numerous national 
guidelines available. Specifically, the ASCO/ASH guidelines state that 11 : 
The use of epoetin is recommended as a treatment option for patients with 
chemotherapy-associated anemia and a hemoglobin concentration that has declined 
to a level less than or equal to 10 g/dL. 
For patients with declining hemoglobin levels but less severe anemia (those with 
hemoglobin concentrations below 12 g/dL but who have never fallen below 10 
g/dL), the decision of whether to use epoetin immediately or to wait until 
hemoglobin levels fall closer to 10 g/dL should be determined by clinical 
circumstances. 
Certainly, these guidelines do not suggest waiting until a person is transfusion dependent 
or has a hemoglobin concentration of less than 90 giL. The lack ofNLPDP coverage is 
likely a large, if not the largest, contributing factor to the low ESA use in anemic cancer 
patients in Newfoundland and Labrador. This is particularly likely to have been the case 
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between 2003 and 2005, during the time period from which data for this study was 
collected. During that time, and subsequently, new data has been emerging that highlight 
important safety concerns around the use of these drugs. This data may have contributed 
to the low ESA use during the study period to some extent, but is perhaps more likely to 
play a role in the future. 
ESAs improve hemoglobin concentrations or hematocrit levels 5 and reduce 
transfusion requirements 6 in anemic patients with malignancies. There is some evidence 
that they also improve quality of life 7. They are, however, known to increase the risk of 
thromboembolic disease 8. An even greater potential risk associated with the use of 
ESAs is twnor progression and decreased survival. The initial clinical evidence for this 
effect was provided by the BEST 9 and ENHANCE trials 10• These trials both had some 
methodological concerns and the majority of patients taking ESAs were not in fact 
anemic. Given the lack of high quality evidence linking ESAs to poorer disease 
outcomes at the time, this concern was likely not a major contributor to the low ESA use 
found in this study. 
In addition to the cost of ESAs and emerging concerns about their safety profile, a 
third possible explanation for the low ESA use found in this study might be the 
demographic features of the sample. One might speculate, for example, that the age of 
the patient could be a factor in the decision about whether to start an ESA. There are 
many potential causes of anemia in older individuals and it may have been felt that 
etiologies other than cancer-related anemia were a greater contributor to some patients' 
anemia. Similarly, place of residence might play a role in determining which patients 
receive ESAs. Given the size of the province and the distance that patients may have to 
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travel to come to St. John's, it is not uncommon for patients to have their chemotherapy 
regimen initiated in St. John's and continued in a rural area of the province. It is possible 
patients seen infrequently by a hematologist or medical oncologist may not have an ESA 
initiated. 
The burden of anemia in this study was represented in three ways: 1) the overall 
average weekly hemoglobin concentration, 2) the proportion of time spent with a 
hemoglobin concentration less than 100 giL and 3) the number of red blood cell 
transfusions that patients received. 
The mean weekly hemoglobin concentration ofthe patients in this study was 89.1 
giL and the patients' hemoglobin concentrations were under 100 giL for about 75% of the 
study weeks. Patients received an average of one red blood cell transfusion every three 
weeks. These results indicate that these patients were significantly anemic and, by 
ASCO/ASH 2002 criteria, should have received an ESA. For some patients, individual 
characteristics may have led to a decision not to use an ESA, for example, a high risk of 
thromboembolism, however these features would likely have applied to a few patients 
only. With approximately 84% of patients not receiving an ESA, it is more likely that 
systemic effects (as discussed above) were responsible. 
The effect of two demographic factors on ESA use in patients with hematologic 
malignancies was examined. No significant difference between the ages of the patients 
receiving and not receiving an ESA was detected. The average age in the group that 
received an ESA was 72.9 years versus 70.1 years in the group that did not. 
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There was significantly more ESA use in patients living in urban areas of the 
province; 61 .1% of patients from urban areas received Eprex versus 38.9% of patients 
from rural areas. It is possible that patients living in rural areas may not have been 
prescribed an ESA as a result of having less contact with a hematologist or medical 
oncologist. 
In summary, the results of this study suggest that 16.4% of patients with 
hematologic malignancies between 2003 and 2005, meeting the 2002 ASCO/ ASH criteria 
for receiving an ESA actually received one. There are several potential reasons for this. 
It may be that the cost of these medications is prohibitive for many patients given that 
NLPDP coverage for them is very limited. The data linking them to poor disease control 
and decreased survival was beginning to emerge during the period from which data were 
collected. This was unlikely to have played a major role, but may have contributed to an 
extent to the low ESA use. Demographic factors may have affected ESA use and the 
results demonstrated that that indeed, more patients from urban areas of the province 
received one. Finally, individual factors, like thromboembolic risk, may have played a 
role. These results also indicate that these patients were significantly anemic. Their 
average weekly hemoglobin was 89.5 giL and for 75% of the study period, hemoglobin 
levels were less than 100 giL. Patients were transfused an average of once every three 
weeks. 
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6.2. Effect of Place of Residence on Receipt of an Erythropoiesis-Stimulating 
Agent 
This study found significantly more ESA use in patients living in urban rather 
than rural areas ofthe province; 61 .1% of patients from urban areas received an ESA 
versus 38.9% of patients from rural areas. This finding is likely related to the fact that 
these drugs are not covered under the provincial drug plan for most patients. Another 
possibility is lesser access to a prescribing hematologist or oncologist. 
In general, Canadians living in rural areas are more likely to live in lower 
socioeconomic conditions, have attained a lower level of education, exhibit less healthy 
behaviours and to have a higher overall mortality rate than their urban counterparts. 79 
While in Canada, access to universally insured health services remains largely unrelated 
to income, many low and moderate income Canadians have limited or no access to 
certain health services and prescription drugs. 80 While in most provinces in Canada, 
erythropoiesis-stimulating agents are covered by the provincial drug plan,81 as described 
above, the criteria for NLPDP coverage ofESAs in Newfoundland and Labrador is 
prohibitive for most patients. 
6.3. The Future of Erythropoiesis-Stimulating Agents 
The clinical benefits associated with the use of ESAs in cancer patients include 
improved hemoglobin or hematocrit, decreased red blood cell transfusions and possibly, 
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improved quality of life. There is an increased risk of thromboembolism in patients 
taking ESAs and questionable decreased survival. 
In order to address new evidence surrounding the use of ESAs in cancer-related 
anemia, ASH and ASCO published a clinical practice guideline update on their use in 
2007 12• These updated guidelines continue to recommend an ESA for patients with 
hemoglobin levels less than 100 giL/, specifica1ly, 
The use of epoetin or darbepoetin is recommended as a treatment option for 
patients with chemotherapy-associated anemia and a Hb concentration that is 
approaching, or has fallen below, 10 g/dL, to increase Hb and decrease 
transfusions. 
These guidelines address the thomboembolic risk by suggesting that clinicians 
"carefully weigh the risks of thromboembolism in patients for whom epoetin or 
darbepoetin are prescribed." The specific risk factors for thromboembolism in patients 
taking these medications have not been defined and therefore established, general risk 
factors for thrombosis should be taken into considered. No studies have yet evaluated the 
use of aspirin or anticoagulants to modulate the risk of thromboembolism in patients 
taking ESAs for cancer-related anemia 
The risk of disease progression while taking an ESA appears to be primarily in 
those patients not receiving concurrent chemotherapy. There is evidence supporting the 
use of ESAs in patients with myelodysplasia 36' 37, however, in other hematologic or solid 
malignancies, they may be associated with an increased risk of death in patients not 
receiving chemotherapy. 
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The decision whether to use an ESA in a patient with cancer-related anemia will 
depend on the benefit-risk ratio for that particular patient. They should be used 
cautiously in patients with risk factors for thromboembolic disease and should not be 
used in patients that are not undergoing chemotherapy. The hematologic response should 
be monitored and the dose titrated to maintain a hemoglobin concentration at or near 120 
giL. In patients in whom there is no hematologic response, the drug should be 
discontinued after a trial period of six to eight weeks. 
6.4. Study Limitations 
For the first part of this study a retrospective design was chosen. The benefit of 
this study design was the fact that practice would not be altered by the study itself. The 
study did have several limitations, primarily: 1) The design was retrospective and 2) 
Information about quality of life and safety was not collected. A retrospective design 
was chosen for its simplicity, low cost, and again so as not to affect practice as the data 
were being collected. If the reason for low ESA use was physician-driven, then 
knowledge of the study might change the way that ESAs were prescribed. One of the 
disadvantages of the retrospective design is the fact that data collection relied on medical 
records, which may have had errors or omissions. Another drawback of the 
retrospective design for this study is that conclusions can only be made about ESA use 
between 2003 and 2005. 
Another limitation is that information about quality of life was not collected. This 
was unfortunately not possible given the study design. It would also be valuable to have 
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safety information about this group of patients. Again, given the study design it would 
have been difficult to ascertain whether side effects could be attributed to the ESA. 
6.5. Future Directions 
Further, high-quality studies are needed to determine more defmitively whether 
ESAs affect quality of life. The specific risk factors for thromboembolic disease in 
patients treated with ESAs must be elucidated, as does whether aspirin or anticoagulation 
can modulate the risk. Finally the effect of ESAs on disease progression and survival 
warrants further study. Given the quality of currently available data, the effect of ESAs, 
titrated to maintain a hemoglobin concentration near 120 giL on a population of patients 
with cancer-related anemia undergoing chemotherapy is still unknown. 
6.6. Conclusions 
For patients with hematologic malignancies in Newfoundland and Labrador, 
ESAs are underutilized. In this study sample, only 16.4% of patients meeting the 2002 
ASCO/ ASH guidelines for the use of ESAs in cancer patients received one. The patients 
were quite anemic with an average hemoglobin of89.1 giL. Hemoglobin concentrations 
were under 100 giL for 75.3% of the study period and patients received an average of one 
red blood cell transfusion every three weeks. Patients living in urban areas of the 
province received an ESA more often than patients in rural areas. 
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ESAs are an important part of supportive cancer care. They improve hemoglobin 
concentrations, decrease transfusion requirements and likely benefit quality of life. The 
factors contributing to the low use of ESAs in this province should be further elucidated 
and measures should be taken to improve their use to meet national and international 
standards of care. Patient selection is important as ESAs increase the risk of 
thromboembolism. There is evidence that ESAs may be harmful in cancer patients not 
undergoing chemotherapy and they should not be used in this group. 
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Appendix A 
Summary of ASCO/ASH Guidelines on the Use ofEpoetin in Cancer Patients 
1. The use of epoetin is recommended as a treatment option for patients with 
chemotherapy-associated anemia and a hemoglobin concentration that has declined to a 
level less than or equal to 10 g/dL. Red blood cell transfusion is also an option depending 
upon the severity of anemia or clinical circumstances. 
2. For patients with declining hemoglobin levels but less severe anemia (those with 
hemoglobin concentration below 12 g/dL but who have never fallen below 10 g/dL), the 
decision of whether to use epoetin immediately or to wait until hemoglobin levels fall 
closer to 10 g/dL should be determined by clinical circumstances. Red blood cell 
transfusion is also a therapeutic option when warranted by severe clinical conditions. 
3. The recommendations are based on evidence from trials in which epoetin was 
administered subcutaneously thrice weekly. The recommended starting dose is 150 U/kg 
thrice weekly for a minimum of 4 weeks, with consideration given for dose escalation to 
300 U/kg thrice weekly for an additional 4-8 weeks in those who do not respond to the 
initial dose. Although supported by less strong evidence, an alternative weekly dosing 
regimen ( 40 000 U/wk), based on common clinical practice, can be considered. Dose 
escalation of weekly regimens should be under similar circumstances to thrice-weekly 
regunens. 
4. Continuing epoetin treatment beyond 6-8 weeks in the absence of response (eg, less 
than 1-2 g/dL rise in hemoglobin), assuming appropriate dose increase has been 
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attempted in nonresponders, does not appear to be beneficial. Patients who do not 
respond should be investigated for underlying tumor progression or iron deficiency. As 
with other failed individual therapeutic trials, consideration should be given to 
discontinuing the medication. 
5. Hemoglobin levels can be raised to (or near) a concentration of 12 g/dL, at which time 
the dosage of epoetin should be titrated to maintain that level or restarted when the level 
falls to near 10 g/dL.lnsufficient evidence to date supports the "normalization" of 
hemoglobin levels to above 12 g/dL. 
6. Baseline and periodic monitoring of iron, total iron-binding capacity {TIBC), 
transferrin saturation, or ferritin levels and instituting iron repletion when indicated may 
be valuable in limiting the need for epoetin, maximizing symptomatic improvement for 
patients, and determining the reason for failure to respond adequately to epoetin. There is 
inadequate evidence to specify the optimal timing, periodicity, or testing regimen for 
such monitoring. 
7. There is evidence from one well-designed, placebo-controlled randomized trial that 
supports the use of epoetin in patients with anemia associated with low-risk 
myelodysplasia, but there are no published high-quality studies to support its use in 
anemic myeloma, non-Hodgkin lymphoma, or chronic lympocytic leukemia patients in 
the absence of chemotherapy. Treatment with epoetin for myeloma, non-Hodgkin 
lymphoma, or chronic lymphocytic leukemia patients experiencing chemotherapy-
associated anemia should follow the recommendations outlined above. 
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8. Physicians caring for patients with myeloma, non-Hodgkin lymphoma, or chronic 
lymphocytic leukemia are advised to begin treatment with chemotherapy and/or 
corticosteroids and observe the hematologic outcomes achieved solely through tumor 
reduction before considering epoetin. If a rise in hemoglobin is not observed following 
chemotherapy, epoetin should be used in accordance with the criteria outlined above for 
chemotherapy-associated anemia if clinically indicated. Blood transfusion is also a 
therapeutic option. 
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Appendix B 
Office ol Research and Graduate Studies !Medicine) 
Faculty ol Medicine 
The Health Sciences Centre 
May 11,2006 
Reference #06.41 
Dr. Dawn Sheppard 
C/o Dr. Kuljit Grewal 
Hematology 
Faculty of Medicine 
Health Sciences Centre 
Dear Dr. Sheppard: 
This will acknowledge the revised application and consent form which you provided 
for your research study entitled "Use of erythropoietin in patients with cancer in 
Newfoundland and Labrador". 
At the meeting held on February 16, 2006, the initial review date of this study, the 
Human Investigation Committee (HI C) agreed that the revised application and 
revised consent form could be reviewed by the Co-Chairs and, if found acceptable, 
full approval of the study be granted. 
The Co-Chairs of the HIC reviewed your correspondence, approved the revised 
application and consent form and, under the direction of the Committee, granted full 
approval of your research study. This will be reported to the full Human 
Investigation Committee, for tl1eir information at the meeting scheduled for May 25, 
2006. 
Full approval has been granted for one year. You will be contacted to complete the 
annual form update approximately 8 weeks before the approval will lapse on 
February 16, 2007. It is your responsibility to ensure that the renewal form is 
forwarded to the HIC office not less than 30 days prior to the renewal date for review 
and approval to continue the study. The annual renewal form can be downloaded 
from the HIC website 
http://www.med.mun.ca/hic/downloads/Annual%20Update%20Form.doc. 
Modifications of the protocol/consent are not permitted without prior approval 
from the Human Investigation Committee. Implementing changes in the 
protoco]/consent without HIC approval may result in the approval of your research 
St. )ohn·s. N L. Canada AlB 3V6 • Tel., 17091 m -6762 • Pa.x, 17091 777·7501 • email' rgso mun.ca 
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Dr. D. Sheppard 
Reference # 06.41 
May 11,2006 
Page 2 
study being revoked, necessitating cessation of all related research activity. 
Request for modification to the protocol/consent must be outlined on an 
amendment form (available on the HIC website) and submitted to the HIC for 
review. 
For a hospital-based study, it is your responsibility to seek the necessary approval 
from the Health Care Corporation of St. John's and/or other hospital boards as 
appropriate. 
This Research Ethics Board (the HJC) has reviewed and approved the application and 
consent form for the study which is to be conducted by you as the qualified 
investigator named above at the specified study site. This approval and the views of 
this Research Ethics Board have been documented in writing. ln addition, please be 
advised that the Human Investigation Committee currently operates according to the 
Tri-Council Policy Statement and applicable laws and regulations. 
Notwithstanding the approval of the HIC, the primary responsibility for the ethical 
conduct of the investigation remains with you. 
We wish you every success with your study. 
Sincerely, 
John D. Harnett, MD, FRCPC 
Co-Chair 
Human Investigation Committee 
JDH;RSN\jd 
RichardS. Neuman, PhD 
Co-Chair 
Human Investigation Committee 
C Dr. C. Loomis, Vice-President (Research}, MUN 
Mr. W. Miller, Director of Planning & Research, HCCSJ 
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D 
Eastern 
Health 
June 14, 2006 
Ms. Dawn Sheppard 
Resident 
C/o Dr. K_ Grewal 
Hematology Oncology 
HSC 
Dear Ms. Sheppard: 
Appendix C 
St. Claro's Mercy Hospital 
154 LeMarcllant Road 
St. John's, NL 
canada A 1 C 5B8 
T: (709) 777-5000 
F: (709) 777-5210 
www.eastemhealth.ca 
Your research proposal "HIC # 06. 041 - Use of erythropoietin in patients with cancer in 
Newfoundland" was reviewed by the Research Proposals Approvals Committee (RPAC) 
of the Health Care Corporation of St. John's at its meeting on June 13, 2006 and we are 
pleased to inform you that the proposal has been approved. 
The approval of this project is subject to the following conditions: 
• The project is conducted as outlined in the HIC approved protocol; 
• Adequate funding is secured to support the project; 
• In the case of Health Records, efforts will be made to accommodate requests 
based upon available resources. If you require access to records that cannot be 
accommodated, then additional fees may be levied to cover the cost; 
• A progress report being provided upon request. 
If you have any questions or comments, please contact Lynn Purchase, Manager of the 
Patient Research Centre at 777-7283. 
s/~No 
MfWa}lfleMiller 
Senior Director, Corporate Strategy & Research 
Chair, RPAC 
cc: Ms. Lynn Purchase, Manager, Patient Research Centre 
Ms. Louanne Kinsella, Program Director Medicine 
Dr. H. Edstrom, Clinical Chief Medicine 
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Appendix A 
Summary of ASCO/ASH Guidelines on the Use ofEpoetin in Cancer Patients 
1 . The use of epoetin is recommended as a treatment option for patients with 
chemotherapy-associated anemia and a hemoglobin concentration that has declined to a 
level less than or equal to 10 g/dL. Red blood cell transfusion is also an option depending 
upon the severity of anemia or clinical circumstances. 
2. For patients with declining hemoglobin levels but less severe anemia (those with 
hemoglobin concentration below 12 g/dL but who have never fallen below 10 g/d.L), the 
decision of whether to use epoetin immediately or to wait until hemoglobin levels fall 
closer to 10 g/d.L should be determined by clinical circumstances. Red blood cell 
transfusion is also a therapeutic option when warranted by severe clinical conditions. 
3. The recommendations are based on evidence from trials in which epoetin was 
administered subcutaneously thrice weekly. The recommended starting dose is 150 U/kg 
thrice weekly for a minimum of 4 weeks, with consideration given for dose escalation to 
300 U/kg thrice weekly for an additional4-8 weeks in those who do not respond to the 
initial dose. Although supported by less strong evidence, an alternative weekly dosing 
regimen ( 40 000 U/wk), based on common clinical practice, can be considered. Dose 
escalation of weekly regimens should be under similar circumstances to thrice-weekly 
regimens. 
4. Continuing epoetin treatment beyond 6-8 weeks in the absence of response (eg, less 
than 1-2 g/d.L rise in hemoglobin), assuming appropriate dose increase has been 
attempted in nonresponders, does not appear to be beneficiaL Patients who do not 
respond should be investigated for underlying tumor progression or iron deficiency. As 
with other failed individual therapeutic trials, consideration should be given to 
discontinuing the medication. 
5. Hemoglobin levels can be raised to (or near) a concentration of 12 g/dL, at which time 
the dosage of epoetin should be titrated to maintain that level or restarted when the level 
falls to near 10 g/dL. Insufficient evidence to date supports the "normalization" of 
hemoglobin levels to above 12 g/dL. 
6. Baseline and periodic monitoring of iron, total iron-binding capacity (TIBC), 
transferrin saturation, or ferritin levels and instituting iron repletion when indicated may 
be valuable in limiting the need for epoetin, maximizing symptomatic improvement for 
patients, and determining the reason for failure to respond adequately to epoetin. There is 
inadequate evidence to specify the optimal timing, periodicity, or testing regimen for 
such monitoring. 
7. There is evidence from one well-designed, placebo-controlled randomized trial that 
supports the use of epoetin in patients with anemia associated with low-risk 
myelodysplasia, but there are no published high-quality studies to support its use in 
anemic myeloma, non-Hodgkin lymphoma, or chronic lympocytic leukemia patients in 
the absence of chemotherapy. Treatment with epoetin for myeloma, non-Hodgkin 
lymphoma, or chronic lymphocytic leukemia patients experiencing chemotherapy-
associated anemia should follow the recommendations outlined above. 
8. Physicians caring for patients with myeloma, non-Hodgkin lymphoma, or chronic 
lymphocytic leukemia are advised to begin treatment with chemotherapy and/or 
corticosteroids and observe the hematologic outcomes achieved solely through tumor 
reduction before considering epoetin. If a rise in hemoglobin is not observed following 
chemotherapy, epoetin should be used in accordance with the criteria outlined above for 
chemotherapy-associated anemia if clinically indicated. Blood transfusion is also a 
therapeutic option. 
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May 11,2006 
Reference #06.41 
Dr. Dawn Sheppard 
Cjo Dr. KuljitGrewal 
Hematology 
Faculty of Medicine 
Health Sciences Centre 
Dear Dr. Sheppard: 
This will acknowledge the revised application and consent form which you provided 
for your research study entitled "Use of erythropoietin in patients with cancer in 
Newfoundland and Labrador". 
At the meeting held on February 16, 2006, the initial review date of this study, the 
Human Investigation Committee (I-IT C) agreed that the revised application and 
revised consent form could be reviewed by the Co-Chairs and, if found acceptable, 
full approval of the study be granted. 
The Co-Chairs of the I-ITC reviewed your correspondence, approved the revised 
application and consent form and, under the direction of the Committee, granted full 
approval of your research study. This wiU be reported to the full Human 
Investigation Committee, for their information a t the meeting scheduled for May 25, 
2006. 
FuU approval has been granted for one year. You will be contacted to complete the 
annual form update approximately 8 weeks before the approval will lapse on 
February 16, 2007. It is your responsibility to ensure that the renewal form is 
forwarded to the HIC office not less than 30 days prior to the renewal date for review 
and approval to continue the study. The annual renewal form can be downloaded 
from the HIC website 
http://www. med.mun.ca/ hie/ downloads/ Annual %20U pda te%20Form.doc. 
Modifications of the protocol/consent are not permitted without prior approval 
from the Human Investigation Committee. Implementing changes in the 
protocol/consent without HIC approval may result in the approval of your research 
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Dr. D. Sheppard 
Reference# 06.41 
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study being revoked, necessitating cessation of all related research activity. 
Request for modification to the protocol/consent must be outlined on an 
amendment form (available on the HIC website) and submitted to the me for 
review. 
For a hospital-based study, it is your responsibility to seek the necessary approval 
from the Health Care Corporation of St. John's and/or other hospital boards as 
appropriate. 
This Research Ethics Board (the HI C) has reviewed and approved the application and 
consent form for the study which is to be conducted by you as the qualified 
investigator named above at the specified study site. This approval and the views of 
this Research Ethics Board have been documented in writing. In addition, please be 
advised that the Human Investigation Committee currently operates according to the 
Tri-Council Policy Statement and applicable laws and regulations. 
Notwithstanding the approval of the HIC, the primary responsibility for the ethical 
conduct of the investigation remains with you. 
We wish you every success with your study. 
Sincerely, 
John D. Harnett, MD, FRCPC 
Co-Chair 
Human Investigation Committee 
JDH;RSN\jd 
RichardS. Neuman, PhD 
Co-Chair 
Human Investigation Committee 
C Dr. C. Loomis, Vice-President (Research), MUN 
Mr. W. Miller, Director of Planning & Research, HCCSJ 
D 
Eastern 
Health 
June 14, 2006 
Ms. Dawn Sheppard 
Resident 
C/o Dr. K. Grewal 
Hematology Oncology 
HSC 
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Sl Clare's Mercy Hospital 
154 LeMarcllanl Road 
Sl John's, NL 
canada A 1 c 588 
T: (709) 777-5000 
F: (709) 777-5210 
WNW.eastemhealth.ca 
Your research proposal "HIC # 06. 041 - Use of el}'ihropoietin in patients with cancer in 
Newfoundland" was reviewed by the Research Proposals Approvals Committee (RPAC) 
of the Health Care Corporation of St. John's at its meeting on June 13, 2006 and we are 
pleased to inform you that the proposal has been approved. 
The approval of this project is subject to the following conditions: 
• The project is conducted as outlined in the HIC approved protocol; 
• Adequate funding is secured to support the project; 
In the case of Health Records, efforts will be made to accommodate requests 
based upon available resources. If you require access to records that cannot be 
accommodated, then additional fees may be levied to cover the cost; 
• A progress report being provided upon request. 
If you have any questions or comments, please contact Lynn Purchase, Manager of the 
Patient Research Centre at 777-7283 . 
. Wayne Miller 
Senior Director, Corporate Strategy & Research 
Chair, RPAC 
cc: Ms. Lynn Purchase, Manager, Patient Research Centre 
Ms. Louanne Kinsella, Program Director Medicine 
Dr. H. Edstrom, Clinical Chief Medicine 




